Operil P

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Operil P

Property Description
Active ingredient Oxymetazoline hydrochloride
Form Aqueous solution (Nasal drops or spray)
Pharmacological class Sympathomimetic agent, Local decongestant
General use Relief of nasal congestion
Origin Synthetic chemical substance

What Type of Medicine is Operil P and What is its Purpose?

Operil P is defined as an established pharmaceutical preparation and a sympathomimetic agent, clinically recognized for its role as a local decongestant to provide effective relief from nasal congestion. This medication, containing Oxymetazoline hydrochloride, belongs to the broader class of adrenergic agonists and functions by stimulating alpha-adrenergic receptors, classifying it as an alpha-adrenergic agonist. Oxymetazoline is used specifically for the localized relief of swelling in the nasal passages. This confirms that the primary function of the medicine is to help clear the stuffiness associated with a blocked nose. Operil P is characterized by its focus on pediatric use, often being formulated in a lower concentration for younger patients compared to standard adult preparations.

Composition and Form: Operil P as an Imidazoline Derivative

The core component responsible for the decongestant effect is the active ingredient, Oxymetazoline hydrochloride, a synthetic chemical substance that is an Imidazoline derivative. This substance is contained within an aqueous solution designed for precise, localized delivery as either nasal drops or a nasal spray. Oxymetazoline causes direct vasoconstriction on the local tissue, supporting its efficacy in reducing nasal swelling. This conclusion indicates that the medicine effectively works by making the blood vessels in the nose narrower. This single-component product achieves its effect by inducing vasoconstriction, which rapidly narrows the local blood vessels, thereby reducing the volume of swollen tissues and decreasing the edema of the nasal mucosa.

What side effects are possible with Operil P?

Possible Side Effects and Safety Information

The safety profile of oxymetazoline, the active ingredient in Operil P, is officially classified based on the types and frequencies of adverse reactions documented in regulatory sources.

Classification of Adverse Reactions

The most frequently documented effects are common local reactions at the administration site. These include nasal dryness, discomfort, burning, stinging, and sneezing. These effects are typically transient.

Less frequently, rare adverse reactions may occur, involving systemic effects. These effects are grouped into system-organ classes such as Cardiac Disorders (e.g., palpitations, tachycardia, increased blood pressure) and Nervous System Disorders (e.g., insomnia, restlessness, headache).

Safety Considerations

The official safety information highlights specific concerns related to the conditions of use and certain populations:

  • Duration-Related Risk: Regulatory labeling explicitly ties prolonged or excessive use beyond the mandated duration limit to the development of rhinitis medicamentosa, commonly known as rebound congestion. This involves the recurrence or worsening of nasal obstruction.
  • Systemic Risk: Because oxymetazoline is a sympathomimetic agent, caution is advised for individuals with pre-existing conditions like hypertension, heart disease, or thyroid disorders.
  • Serious Adverse Reactions: Serious events, including convulsions, coma, and severe bradycardia, are officially documented in regulatory sources following accidental oral ingestion or significant overdose, particularly in children.
  • Interactions: The label notes a potential increased risk of cardiovascular effects, such as heightened blood pressure, when this medicine is used alongside certain other medications, like Monoamine Oxidase Inhibitors.

Overdose and Emergency Response

Operil P contains oxymetazoline, a nasal decongestant. Overuse or accidental ingestion, particularly by children, can result in serious systemic effects due to its alpha-adrenergic agonist properties. This risk is especially significant in children under the age of six.

Overdose Manifestations

Overdose or ingestion of oxymetazoline may cause central nervous system (CNS) depression, which can range from marked sedation to coma. Key physiological symptoms that may be observed include:

  • Cardiovascular: Fast or slow heartbeat (bradycardia or tachycardia), and high blood pressure.
  • Neurological: Severe drowsiness, dizziness, or lethargy.
  • Respiratory: Depressed breathing (respiratory depression) or shallow breathing.
  • Other: Nausea, vomiting, and difficulty falling or staying asleep.

When to Seek Emergency Help

Immediate medical attention is required if a person uses an excessive dose or accidentally swallows the solution, even if only a small amount (such as 1–2 mL) is ingested, especially in young children. Serious adverse reactions reported in such cases require prompt medical evaluation and potential hospitalization. In any situation involving suspected overdose, contact a poison control center or emergency services right away.

Therapeutic Uses of Operil P

Operil P is commonly used for managing symptoms related to congestion and swelling of the nasal passages. It is applied across therapeutic domains where short-term symptomatic assistance is needed to manage discomfort and support functional stability.

This medication is used to relieve nasal discomfort, sinus congestion, and pressure associated with common colds, hay fever, and allergies.

Therapeutic Symptom Domains

The medication is generally applied in clinical settings that involve acute or unstable symptom patterns, helping to ease symptoms that create noticeable physiological strain, specifically nasal obstruction and stuffiness. Operil P is considered relevant across conditions presenting with acute episodes and is commonly used for managing symptoms in contexts like: Acute rhinitis (common cold congestion), Allergic rhinitis (hay fever), and Rhinosinusitis (sinus trouble).

This approach provides supportive relief when symptoms interfere with routine activities and contributes to improved day-to-day comfort.

“The use of this medication is aligned with the goal of helping maintain a sense of stability when nasal symptoms become more noticeable, particularly during acute flare-ups.”

The medication may also be part of symptomatic management in scenarios where congestion contributes to issues concerning the middle ear.


Quick Fact: Focus on Congestion Relief

Operil P is relevant for easing congestion that is sudden, episodic, and associated with symptoms related to inflammatory or irritative states.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Operil P’s eligibility profile is strictly defined by official regulatory criteria, primarily related to its classification as a sympathomimetic agent.

Contraindications (Absolute Non-Eligibility)

The medicine is strictly contraindicated for patients with known hypersensitivity to oxymetazoline. Absolute non-eligibility extends to individuals with narrow-angle glaucoma, rhinitis sicca (dry nasal inflammation), or those who have undergone surgery involving the dura mater, such as trans-sphenoidal hypophysectomy. Furthermore, the product must not be used by patients currently taking Monoamine Oxidase Inhibitors (MAOIs) or who have stopped them within the last 14 days.


Restricted Populations and Conditions

The product is not recommended for children under 2 years of age. For children between 2 and 6 years, the lower-strength formulation (like Operil P) is indicated. Use requires special caution in patients with severe cardiovascular disease, hypertension, hyperthyroidism, or diabetes mellitus. For pregnant or breastfeeding women, use is generally not recommended and requires consultation, as safety has not been established by regulatory bodies.

What should I know about interactions with other medicines?

The official regulatory profile for Oxymetazoline hydrochloride is structured around interactions that are documented to create systemic sympathomimetic effects or alter local absorption rates.

Contraindicated and Restricted Combinations

The use of this product is contraindicated with Monoamine Oxidase Inhibitors (MAOIs), a drug class that includes medicines like Isocarboxazid and Phenelzine. This restriction is based on the potential for severe pharmacodynamic reinforcement, which carries a documented risk of resulting in a hypertensive crisis. A strict regulatory condition mandates that the product must not be used for up to 14 days following the discontinuation of MAOI therapy.

Pharmacodynamic and Antagonistic Interactions

Significant pharmacodynamic interactions are also documented with other drug classes. Co-administration with Tricyclic Antidepressants (TCAs) may lead to an officially noted increased risk of Hypertension and Arrhythmias. The effects of certain Antihypertensive Drugs, including beta-blockers, may be antagonised (reduced) when used concurrently. There is also a documented possibility of additive cardiovascular toxicity when co-administered with certain Anti-parkinsonian medications.

Other Interactions and Consumables

In terms of local pharmacokinetic interactions, the product may slow the rate of absorption of other medicines administered intranasally. Official regulatory labeling indicates no formal, specific interaction is known or documented for co-use with food, alcohol, or common herbal products.

Mechanism of Action

Adrenergic Receptor Activation and Vascular Signaling

Operil P (Xylometazoline) functions as an alpha-adrenergic receptor agonist, selectively targeting receptors present on the smooth muscle cells of blood vessels within the nasal mucosa. By binding to these receptors, the compound initiates an intracellular signaling cascade characteristic of the sympathetic pathway. This molecular interaction mimics the effects of endogenous adrenergic mediators, leading to an increase in intracellular calcium ion concentration.


Modulation of Local Blood Flow and Tissue Volume

This calcium-dependent signaling drives the subsequent contraction of vascular smooth muscle cells (vasoconstriction). Vasoconstriction is a physiological process that limits the volume of blood within the capillaries and venous sinuses of the nasal lining, thereby modulating the local fluid dynamics and circulatory processes. This mechanism engages key regulatory systems to reduce heightened vascular pathway activity.


Physiological Detumescence

The ultimate physiological consequence of this localized vascular mechanism is detumescence—the decrease in tissue volume. By altering local microcirculation dynamics, the compound modulates the overactive physiological processes in the nasal vasculature, influencing the subsequent anatomical adjustments that shape the drug's effect profile.

Dosage and Administration Information

The administration of Oxymetazoline hydrochloride solution, the active component of Operil P, is confined to the intranasal route, using either drops or a spray device for topical application to the nasal lining. The product is administered using two distinct concentrations: the 0.05% strength is designated for adults and children 6 years of age and older, while a 0.025% concentration is formulated specifically for pediatric patients between 2 and 6 years of age. Children in this younger age group must be supervised by an adult during the application process to ensure proper use.

The standardized dosing regimen involves administering 2 or 3 sprays or drops into each nostril per application. Usage frequency is strictly monitored, with the official label mandating that the medicine be applied not more often than every 10 to 12 hours, meaning administration must not exceed two doses within any 24-hour period.

A critical component of the official usage protocol is the temporal restriction: the medicine is intended for short-term use only, and administration should be strictly limited to a maximum of three consecutive days to conform to regulatory guidelines. Procedurally, administration should occur with the head held upright when using the spray, not tilted backward. Following application, the device nozzle must be wiped clean, and the container should never be shared among individuals, a requirement designed to mitigate potential infection spread.

Recent Clinical Evidence

Research evidence / Overview of studies for Operil P

Evidence for Use in Acute Rhinitis (Common Cold Congestion)

Research examining the substance was studied for nasal congestion associated with acute rhinitis (common cold) and has largely relied on numerous double-blind, vehicle-controlled Randomized Controlled Trials (RCTs) and subsequent systematic reviews. These studies were used in research exploring how symptoms change over time in healthy adults. Research examined outcomes related to physical discomfort using patient-reported scores of stuffiness, alongside objective measures such as rhinomanometry, which assesses nasal airflow.

Studies monitoring short-term changes consistently monitored objective outcomes describing temporary changes in nasal airflow and resistance during the study period, compared to an inactive vehicle. Findings describe patterns observed in the studies related to measured changes in nasal stuffiness. Long-term outcomes and the implications of extended use beyond the maximum duration of use defined in studies are not fully established by dedicated, long-duration research.

Evidence for Use in Persistent Nasal Obstruction

The substance was studied for outcomes related to persistent nasal obstruction, such as in patients with allergic or non-allergic rhinitis. Research explored short-term changes and intermediate treatment periods, often evaluating the substance as a component of a fixed-dose combination with other standard treatments. Research examined patient-reported outcomes describing perceived discomfort and functional measures like Quality of Life (QoL) metrics.

Evidence is limited in characterizing the substance’s role as a standalone treatment for persistent nasal obstruction. Follow-up durations were limited, and the risk of rebound congestion associated with prolonged use is a limitation noted by researchers. Therefore, data for long-term maintenance treatment of chronic nasal obstruction are not well-established.

Evidence in Pediatric Populations

Operil P has been studied for use in children aged 6 years and older, reflecting its lower-concentration formulation. Clinical reports described the assessment of nasal obstruction in children and studies explored short-term changes in the symptom over short durations of use. Studies also examined use in specialized settings, such as pediatric patients undergoing elective surgery where research examined temporary physiological imbalance.

What is Still Uncertain About the Research Record

Certainty remains low regarding long-term effects, as follow-up durations were limited in the primary studies. Furthermore, data for certain groups remain insufficient, particularly regarding pharmacokinetic research in children younger than six years old, which is noted by regulatory bodies. Evidence quality varies across studies, and some systematic reviews indicate that the results apply only to the populations studied.

Key Studies & References

  1. MedlinePlus Drug Information: Oxymetazoline Nasal Spray (Regulatory/Safety Context)

Frequently Asked Questions (FAQ)

Common questions about Operil P (FAQ)


Q: Is Operil P the same as regular Operil, and if not, what's the difference?

Official product information describes Oxymetazoline formulations using different concentrations. The 'P' often denotes a formulation with a lower concentration of the active ingredient, which is intended for use in younger children. A higher concentration is generally designated for use by adults and children aged 6 years and older.


Q: What kind of congestion is Operil P intended to treat?

Regulatory documents indicate that this medicine is used for the temporary relief of nasal congestion associated with conditions such as the common cold, hay fever, and upper respiratory allergies. Certain official labels also include indications for allergic rhinitis and rhinosinusitis.


Q: Can Operil P help with post-nasal drip feeling?

The medicine’s mechanism involves vasoconstriction, which means it narrows the blood vessels in the nasal lining to reduce swelling and improve nasal airflow. While this mechanism is intended to clear nasal passages, regulatory documents do not specifically mention 'post-nasal drip' or guarantee relief from that symptom.


Q: Is Operil P a steroid or does it contain any cortisone?

The active ingredient, Oxymetazoline, is officially categorized as a sympathomimetic agent and an alpha-adrenergic agonist. Its classification is not that of a steroid or corticosteroid.


Q: Why do some people say Operil P can make them feel shaky or nervous?

Official adverse effect listings report rare systemic reactions related to the central nervous system, including restlessness, insomnia, and headache. These effects are associated with the sympathomimetic nature of the medicine and its potential systemic absorption, according to official adverse event reports.


Q: Can Operil P make it hard to sleep if I use it late in the day?

The official safety profile lists insomnia (difficulty sleeping) as a possible rare adverse effect. Because the medicine can cause restlessness and insomnia, users may need to be mindful of using it close to bedtime.


Q: Can Operil P cause dry mouth or nose?

Yes, regulatory information lists dryness of the nasal mucosa, along with stinging or burning, as common local adverse reactions at the application site. Some official labels also note that dry mouth is a potential systemic effect.


Q: Does using Operil P affect the results of any common medical tests?

Official labeling suggests that topically applied sympathomimetic agents can be absorbed into the body and may cause slight increases in blood glucose concentrations. Because of this, specific patient groups, such as those with diabetes mellitus, may need to monitor their blood glucose levels.


Q: Is Operil P available without a prescription, and if so, where?

According to major regulatory bodies, the active ingredient Oxymetazoline in its nasal spray/drop formulation is generally approved and available as an Over-the-Counter (OTC) medicine.


Q: What scientific studies support the use of Operil P for nasal congestion?

Regulatory approval is based on evidence from controlled clinical studies, such as Randomized Controlled Trials (RCTs). These studies typically measure outcomes like improved nasal airflow and reduced congestion symptoms over short-term periods compared to an inactive substance.


Q: Why do doctors sometimes prescribe Operil P instead of oral decongestants?

This medicine is administered via the intranasal route for a localized effect. This targeted delivery is intended to work locally on the nasal lining, which is a key difference from medicines taken orally that act systemically throughout the body.


Q: Why does Operil P sometimes cause a temporary increase in nasal discharge?

Official regulatory labels state that some users may experience temporary local discomfort when using the product. This discomfort may include burning, stinging, or a temporary increase in nasal discharge.


Q: What are the signs of someone becoming dependent on nasal decongestants like Operil P?

Regulatory warnings describe the risk of rhinitis medicamentosa, commonly known as rebound congestion, with prolonged or excessive use beyond the mandated time limit. This condition is characterized by the worsening or recurrence of nasal obstruction as the medication wears off, potentially leading to the need for more frequent or continuous use.


Q: Does Operil P have any known interactions with herbal supplements?

Official drug labeling indicates that no formal, specific interaction is known or documented for the use of this product alongside common food, alcohol, or herbal products.


Q: Why is proper head position important when administering Operil P?

The head should be held upright during use, according to official directions. This procedure helps the medicine properly reach the nasal lining and reduces the likelihood of it dripping into the throat.


Q: Does Operil P contain benzalkonium chloride or any other preservatives?

Yes, official regulatory documents, which list the inactive ingredients, indicate that benzalkonium chloride is commonly included as a preservative in many Oxymetazoline formulations.


Q: Are there different strengths or formulations of Operil P available?

Official product information describes that the active ingredient is available in different strengths, with the adult formulation and the lower concentration pediatric formulation being common.


Q: Can the spray tip of Operil P transmit infection if not cleaned?

Regulatory warnings emphasize that the nozzle should be wiped clean after each use and that the container should never be shared. This is a critical requirement designed to prevent the potential spread of infection among users.


Q: Can Operil P trigger headaches in some users?

Official adverse event reports list headache as a potential rare systemic side effect. This is related to the medication's sympathomimetic action and subsequent absorption into the bloodstream.

How should Operil P be stored and disposed of?

How to Store and Dispose of Operil P?

Strict storage and disposal requirements are defined in official regulatory labeling to ensure product stability and safety.

Storage Category Official Requirement
Temperature Store at controlled room temperature, generally between 20 C and 25 C. Do not freeze the medication.
Protection Keep the medication in the original container, tightly closed. Store away from excess heat, direct light, and moisture.
Child Safety Store securely, completely out of the sight and reach of children. Accidental ingestion poses a risk of serious harm.
Handling To prevent the spread of infection, do not share the dispenser. Clean the tip after each use.
Disposal The preferred method is disposal through an authorized drug take-back program. If unavailable, mix the unused medicine with an unappealing substance, place it in a sealed bag, and discard it in household trash. Do not flush down the toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Operil P found in:

A-Z Index: